이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

염증성 관절염 환자의 안전 기술 향상을 위한 자가 관리 스마트폰 앱의 효과 (RHUMATOSMART)

2026년 11월 5일 업데이트: Assistance Publique - Hôpitaux de Paris

항류마티스 약물로 치료받는 염증성 관절염 환자의 안전 기술 증진을 위한 자가 관리 스마트폰 애플리케이션의 효과

Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis. These include conventional DMARDs such as methotrexate, as well as targeted DMARDs (tDMARDs), i.e., biological agents (bDMARDs) like anti-TNF alpha and JAK inhibitors. Patients treated with tDMARDs face a risk of adverse effects, including an increased risk of infections. Therapeutic patient education has been shown to help patients develop safety skills, but its effectiveness is only short-term.

Mobile health applications are increasingly used by patients to manage their health.

The French Society of Rheumatology (SFR) has developed a smartphone self-management application aimed at supporting people with inflammatory arthritis in managing their treatments, symptoms, and information needs. It provides advice on lifestyle and daily living, promotes treatment adherence, and enables self-assessment of disease status. The app includes seven features: a safety checklist before treatment administration, daily life aids based on French academic recommendations, treatment reminders, self-assessment of overall well-being, disease monitoring (pain, fatigue, patient global assessment of disease activity), periodic advisory messages, and a diary.

The application is not a medical device; collected data are stored on the user's smartphone. Patient data are not directly shared with physicians. Patients can use the app during consultations or share screenshots with their doctors. The app is more widely used and has a longer lifespan than most available apps, but its impact on patients still needs evaluation in a randomized controlled trial.

The primary hypothesis of the study is that using the app will improve safety skills in patients with inflammatory arthritis treated with tDMARDs compared to usual care, including access to the SFR patient information website.

The secondary hypothesis is that using the app will improve patient adherence and the patient-rheumatologist relationship.

Objectives : To determine whether the mobile application improves patients' ability to acquire safety-related skills in the daily use of targeted disease-modifying antirheumatic drugs (tDMARDs), compared to usual care, including access to an informational website for patients.

The primary outcome will be the change in the BioSecure questionnaire score at 6 months after inclusion, comparing the group using the mobile application with the group using the informational website.

연구 개요

상세 설명

Rheumatoid arthritis (RA) and spondyloarthritis (SpA) including psoriatic arthritis (PsA) represent painful chronic conditions impairing quality of life and work capacities. Disease-modifying anti-rheumatic drugs (DMARDs) are used to control inflammatory Arthritis (IA) disease activity, reduce functional disability and improve prognosis. They include conventional DMARDS (cDMARDs) such as methotrexate, targeted DMARDs (tDMARDs) i.e biologic agents (bDMARDs) such as tumor necrosis factor (TNF) alpha blockers, and Janus-kinase inhibitors (JAKi). The number of DMARDs is increasing (more than 15 DMARDs in France) and have a wide variety of targets and modes of administration . Patients treated by DMARDs are at risk of adverse events, including excess risk of infection, noted more in RA than SpA , in particular because of co-medication with glucocorticoids and/or high disease activity. Measures patients can take to decrease these risks include vaccinations , self-referral and DMARD interruption in some situations such as surgery, dental care or pregnancy, which patients need to discuss with health professionals. A nurse-led patient education has been shown to be effective in promoting safety skills of patients treated by biologics but education is not routinely provided in all rheumatology centres. Moreover, patient education is effective in the short term only, not exceeding 6 months .

Mobile health applications (mhealth apps) have undergone significant development in recent years and are of increasing interest and usefulness to help patients manage their chronic inflammatory arthritis (IA) . With reference to the well-established definition of self-management . that is, "the ability of the individual to manage symptoms, treatment, lifestyle changes and psychosocial and cultural consequences of health conditions", Apps may be appropriate tools for self-management such as medications management, problem-solving, and care coordination or to offer a more holistic approach . However, an app providing information to help patients be more aware of their medications in daily life and adopt appropriate behaviours with risk situations had not been addressed in IA.

In this context, the French Society of Rheumatology ( SFR) developed a self-management smartphone app, with the objective of helping IA people with their treatments, symptoms, and information needs, provide healthy lifestyle and daily life messages and promote adherence to medication and disease self-assessment . The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary. The app is not a medical device, data collected are stored within the user's smartphone. Patients' data are not to be directly communicated to the physicians, but patients can make screenshots of their app to communicate with their physician. The app was installed 20,500 times from September 2017 to October 2020 (nowadays 30,000 downloads), with 4300 regular current users. Scores were 4.4/5 stars at Android and iOS stores . The SFR app is the first published app with respect to medication management, all the more in France where very few health apps are available. Apart from SFR app, only one app has been published on medication management, tested on 85 patients . The SFR app is more widely used and has a longer lifespan than most apps available in IA: in the studies by EULAR, 75% people had stopped using m-health apps after 3 months for rheumatic and musculoskeletal diseases and only 5% of these apps were still available 2 years after their launch . Assessment of the impact of the SFR app is important since patients are more likely to download and use the app if it has a proven benefit and 2/3 of patients would use it if recommended by their physicians . Therefore, the impact of SFR app needs to be evaluated in a randomised controlled trial.

The first hypothesis of the study is that the use of the SFR app would promote safety skills of patients with IA treated with DMARDs, compared with usual care including access to a SFR patient information website.

The secondary hypothesis is that the use of the SFR app would promote adherence to tDMARDs and patient-rheumatologist's relationship.

연구 유형

중재적

등록 (추정된)

144

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Paris, 프랑스, 75012
        • 모병
        • Rheumatology Hopital Saint Antoine
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age between 18 and 75 years
  • Diagnosis of rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria of the American College of Rheumatology, or axial or peripheral spondyloarthritis (SpA) according to the 2009 ASAS criteria of the Assessment of SpondyloArthritis International Society, or psoriatic arthritis according to the 2009 CASPAR criteria.
  • Undergoing a treatment change to a tDMARD (biologic or JAK inhibitor) available in the SFR application.
  • No therapeutic education on tDMARDs in the past two years.
  • Ability to use a smartphone application.
  • Ability to use a website.
  • Ability to complete a questionnaire.
  • Signed informed consent for the study.
  • Covered by social security or entitled to social protection.

Exclusion Criteria:

  • Any condition that may affect comprehension or treatment adherence (chronic alcoholism, language barrier, severe psychiatric disorders, cognitive impairment).
  • Planned treatment with intravenous bDMARDs in the upcoming year.
  • Patients who have already downloaded self-management applications for their rheumatic disease.
  • Patients enrolled in a therapeutic education program: face-to-face education by a nurse or healthcare professional, or group education.
  • Patients who have already received therapeutic education on targeted DMARDs in the past two years: face-to-face education by a nurse or healthcare professional, or group education.
  • Participation in another interventional clinical trial
  • Pregnant or breast-feeding woman
  • Individual under legal protection (tutorship or guardianship) or deprived of freedom

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Mobile Application

Patients in the intervention group will upload the SFR app

The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary.

간섭 없음: information web site

Patients of both group willreceive a link that will give them access to SRF web site

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
safety skills regarding the use of tDMARDS
기간: 6 month

safety skills regarding the use of tDMARDS will be assessed by the change of the updated BioSecure questionnaire score at 6 months from baseline in the SFR mobile app group versus the control group.

The scores ranges from 0 to 50. A higher scores represents higher safety skills.

6 month

2차 결과 측정

결과 측정
측정값 설명
기간
Adherence to tDMARDs
기간: 6 month

Adherence to tDMARDs assessed by the CQR5 questionnaire score (rate of adherent patients).

The scores ranges from 4 to 20, with a high score indicating better adherence.

6 month
patient-rheumatologist communication
기간: 6 month

Patient-rheumatologist communication assessed by the PEPPI-5 questionnaire score (Perceived Efficacy in Patient-Physician Interactions).

The scores ranges from 0-50; higher scores represent higher perceived self-efficacy in patient-physician interactions.

6 month
confidence in taking care of one's health
기간: 6 month

Health confidence assessed by the HCS questionnaire (Health confidence score).

The scores ranges from 0 to 12. Higher score represents greater health confidence.

6 month
Impact on disease including coping to disease.
기간: 6 month

Impact of disease assessed by the RAID questionnaire score (rheumatoid arthritis impact of disease).

6 month
Disease activity for rheumatoid arthritis
기간: 6 months

Disease activity assessed by the RADAI (Rheumatoid Arthritis Disease Activity Index),

The scores ranges from 0-48, higher score meaning higher disease activity

6 months
Disease activity for axial spondyloarthritis
기간: 6 months

Disease activity assessed by the BASDAI (Bath Ankylosing Spondylitis Disease activity).

The scores ranges from 0 to 10, higher score meaning higher disease activity.

6 months
Disease activity for psoriatic arthritis
기간: 6 months

Disease activity assessed by SASPA (Stockerau Activity Score for Psoriatic Arthritis).

The scores ranges from 0 to 5, higher score meaning higher disease activity.

6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Catherine BEAUVAIS, Medical Doctor, Assistance Publique - Hôpitaux de Paris

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 8월 31일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2027년 9월 1일

연구 등록 날짜

최초 제출

2026년 1월 5일

QC 기준을 충족하는 최초 제출

2026년 3월 4일

처음 게시됨 (실제)

2026년 3월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다